A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This multicenter, randomized, double-blind, placebo-controlled, two-arm, parallel-group study
will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in participants with
systemic sclerosis. Participants will be randomized to receive either RoActemra/Actemra 162
mg subcutaneously weekly or placebo for 48 weeks. From Week 48 to Week 96, all participants
will receive open-label RoActemra/Actemra 162 mg subcutaneously weekly. Anticipated time on
study treatment is 96 weeks.